# 4See Ventures

> 4See Ventures is a VC fund in Secheron backing Medical and Health Care. See 7 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Secheron, Switzerland
- Total investments: 7
- Last investment: Oct 2025
- Lead investor: 14%
- Last updated: Aug 2026
- Website: https://4seeventures.ch/

4see ventures is a Swiss venture capital firm investing in exceptional entrepreneurs who are defining the future. We focus on real game-changers in their industries who are having a positive impact on society.

## Contacts

5 contacts available for 4See Ventures. Shizune tracks 1 team members at 4See Ventures. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/4see-ventures?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $3.5M–$20M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 2 | 29% |
| Health Care | 2 | 29% |
| SaaS | 1 | 14% |
| Mobile | 1 | 14% |
| Genetics | 1 | 14% |

14 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 3 | 43% |
| Series A | 1 | 14% |
| Series C | 1 | 14% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Switzerland | 4 | 57% |
| Israel | 1 | 14% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Daniel Bertholet | Founder and Managing Partner | 4 | https://shizune.co/investors/profile/daniel-bertholet |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| FenX | FenX is a recyclable insulating product that turns mineral waste into usable resources to support a circular economy. Real estate developers, construction companies, and architects can now access non-flammable insulation materials for construction processes. the company's portfolio of recyclable insulation materials, which includes foamproducts and foam formulations made from readily available waste or natural materials with CO2 emissions. | $10.3M | Series A | Oct 01, 2025 |  |
| PowerAPI | Foodetective enables F&B businesses to integrate & manage their entire tech stack from a single OS & platform. Increasing online revenues and visibility as well as removing all operational & administrative tasks. Our vision is to become the intelligent OS & interface of the F&B industry. | $3.5M | Seed | Dec 22, 2023 |  |
| HAYA Therapeutics | HAYA Therapeutics is a biotechnology company developing precision RNA-guided medicines that target the dark genome. The company leverages its proprietary platform to uncover new insights into disease-associated cell states and the long non-coding RNAs (lncRNAs) that control them. Its lead candidate, HTX-001, is being developed as a potentialtreatment for heart failure. In addition, the company is advancing a pipeline of precision therapies that target lncRNAs for cell-specific treatment of conditions affecting other tissues. | $5M | Seed | Feb 09, 2022 |  |
| CYSEC | CYSEC is a startup working on next generation Confidential Computing solutions securing data at rest, in motion and in use. Currently they have released their ARCA solution which is quickly becoming one of the more popular choices in the market. | $4.4M | Seed | Jan 20, 2022 |  |
| HAYA Therapeutics | HAYA Therapeutics is a biotechnology company developing precision RNA-guided medicines that target the dark genome. The company leverages its proprietary platform to uncover new insights into disease-associated cell states and the long non-coding RNAs (lncRNAs) that control them. Its lead candidate, HTX-001, is being developed as a potentialtreatment for heart failure. In addition, the company is advancing a pipeline of precision therapies that target lncRNAs for cell-specific treatment of conditions affecting other tissues. | $20.1M | Seed | May 20, 2021 |  |
| HAYA Therapeutics | HAYA Therapeutics is a biotechnology company developing precision RNA-guided medicines that target the dark genome. The company leverages its proprietary platform to uncover new insights into disease-associated cell states and the long non-coding RNAs (lncRNAs) that control them. Its lead candidate, HTX-001, is being developed as a potentialtreatment for heart failure. In addition, the company is advancing a pipeline of precision therapies that target lncRNAs for cell-specific treatment of conditions affecting other tissues. | $18M | Seed | May 05, 2021 |  |
| keepMED | keepMED develops a device for treatment of Obstructive Sleep Apnea, a disorder characterized by repetitive episodes of upper airway obstruction that occur during sleep. | $15.3M | Series C | Sep 29, 2020 |  |

7 of 7 investments shown.

## Co-investors
- [Apollo Health Ventures](https://shizune.co/investors/profile/apollo-health-ventures) — VC Fund, 3 deals together
- [Bernina BioInvest](https://shizune.co/investors/profile/bernina-bioinvest) — VC Fund, 3 deals together
- [Broadview Ventures](https://shizune.co/investors/profile/broadview-ventures) — VC Fund, 3 deals together
- [Schroder Adveq](https://shizune.co/investors/profile/schroder-adveq) — VC Fund, 3 deals together
- [Viva BioInnovator](https://shizune.co/investors/profile/viva-biotech) — VC Fund, 3 deals together
- [Arbevel](https://shizune.co/investors/profile/arbevel) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [SICTIC](https://shizune.co/investors/profile/sictic) — VC Fund
- [Zürcher Kantonal Bank](https://shizune.co/investors/profile/z%C3%BCrcher-kantonalbank) — VC Fund
- [Foundation for Innovation and Technology (FIT)](https://shizune.co/investors/profile/foundation-pour-l-innovation-technologique) — VC Fund

## Featured in investor lists
- [Medical VC Funds in Switzerland](https://shizune.co/investors/medical-vc-funds-switzerland)
- [Biotechnology VC Funds in Switzerland](https://shizune.co/investors/biotechnology-vc-funds-switzerland)
- [Biotech VC Funds in Switzerland](https://shizune.co/investors/biotech-vc-funds-switzerland)
- [Biotechnology Investors in Switzerland](https://shizune.co/investors/biotechnology-investors-switzerland)
- [Biotech Investors in Switzerland](https://shizune.co/investors/biotech-investors-switzerland)
- [Restaurants VC Funds in Switzerland](https://shizune.co/investors/restaurants-vc-funds-switzerland)

## FAQ

### What does 4See Ventures invest in?

4See Ventures invests primarily in Medical, Health Care and SaaS startups, most often at Seed and Series A stage. Most of the 7 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is 4See Ventures's check size?

4See Ventures typically joins rounds of $3.5M–$20M at Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds 4See Ventures participates in.

### How do I contact 4See Ventures?

Public channels for 4See Ventures include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at 4See Ventures?

The team at 4See Ventures includes Daniel Bertholet (Founder and Managing Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co